Immunotoxins are proteins that contain a toxin along with an antibody or growth factor that
binds specifically to target cells. Nearly all protein toxins work by enzymatically inhibiting …

Accumulating evidence suggests that the clinical efficacy of selected anticancer drugs,
including conventional chemotherapeutics as well as targeted anticancer agents, originates …

Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a
novel or reinstating a pre-existing antitumor immune response. Most often …

Abstract Overexpression of Bcl-2/Bcl-XL protein has been observed in more than 80% of B-
cell lymphomas. Diffuse large cell lymphoma (DLCL) is the most common subtype of non …

Successful translation of modern molecular immunology into effective cancer
immunotherapy is threatened by regulatory barriers and challenges to the development of …

Toll-like receptors (TLRs) are an evolutionarily conserved group of enzymatically inactive,
single membrane-spanning proteins that recognize a wide panel of exogenous and …

Tumor-targeting immune responses provide a significant contribution to (when they do not
entirely account for) the clinical activity of diverse antineoplastic regimens, encompassing …

Immunotoxins, composed of protein toxins connected to cell binding ligands including
monoclonal antibodies and growth factors, have been developed for several decades to …

Over the years, the unique capacity of dendritic cells (DC) for efficient activation of naive T
cells has led to their extensive use in cancer immunotherapy protocols. In order to be able to …

Although rituximab, a chimeric monoclonal antibody that specifically binds to CD20, has
significantly improved the prognosis for diffuse large B cell lymphoma (DLBCL), one‐third of …